Brean Capital Assumes CytoSorbents (CTSO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
CytoSorbents (CSTO) Bullish View Reiterated at Maxim Group on Commercial Launch of CytoSorb for Cardiac Surgery
October 4, 2016 12:16 PM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $8 price target on CytoSorbents (NASDAQ: CTSO) after the company announced its strategic partner Terumo Cardiovascular Group has initiated international commercialization of CytoSorb for use during complex cardiac surgery at the European Association for Cardio-Thoracic Surgery (EACTS) conference in Barcelona, Spain... More
